OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 01:59 UTC. Every row links to its source record.

RECQL4 RecQ like helicase 4

ENSG00000160957 · protein coding · Open Targets profile

An ATP-dependent DNA helicase which unwinds dsDNA with a 3'- overhang in a 3'-5' direction (PubMed:28653661). Does not unwind more than 18 bp of dsDNA (PubMed:28653661). May modulate chromosome segregation. The N-terminal domain (residues 1-54) binds DNA Y-shaped DNA better than ss- or dsDNA (PubMed:22730300). The core helicase domain binds ssDNA (PubMed:22730300, PubMed:28653661). {ECO:0000269|PubMed:15317757, ECO:0000269|PubMed:22730300, ECO:0000269|PubMed:28653661}.

In 11 of 15 cancers, the evidence for RECQL4 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751Rothmund-Thomson syndrome type 2Rothmund-Thomson syndrome type 2Rothmund-Thomson syndrome type 2: germline 0.88Rothmund-Thomson syndromeRothmund-Thomson syndromeRothmund-Thomson syndrome: germline 0.86osteosarcomaosteosarcomaosteosarcoma: somatic 0.46hereditary neoplastic syndromehereditary neoplastic syndromehereditary neoplastic syndrome: germline 0.86ovarian cancerovarian cancerovarian cancer: germline 0.68esophageal squamous cell carcinomaesophageal squamous cell carcinomaesophageal squamous cell carcinoma: somatic 0.61prostate carcinomaprostate carcinomaprostate carcinoma: somatic 0.61non-small cell lung carcinomanon-small cell lung carcinomanon-small cell lung carcinoma: somatic 0.61lung carcinomalung carcinomalung carcinoma: somatic 0.61colorectal adenocarcinomacolorectal adenocarcinomacolorectal adenocarcinoma: somatic 0.61skin squamous cell carcinomaskin squamous cell carcinomaskin squamous cell carcinoma: somatic 0.61Dysplasia in Ulcerative ColitisDysplasia in Ulcerative ColitisDysplasia in Ulcerative Colitis: somatic 0.61hemangioblastomahemangioblastomahemangioblastoma: somatic 0.61thyroid tumorthyroid tumorthyroid tumor: somatic 0.61cecum adenocarcinomacecum adenocarcinomacecum adenocarcinoma: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
Database Ubiquitination

gnomAD loss of function constraint: o/e 1.2281999588012695 (upper bound 1.4014999866485596). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of RECQL4's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of RECQL4's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.